Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene's Invir.IO Platform

Transgene to receive $8 million upfront option exercise payment Conference call today on December 15, 2021, at 6:00 p.m. CET (12:00 p.m. ET) in English (details at the end of the release) Regulatory

Related Keywords

United States ,Paris ,France General ,France ,United Kingdom ,Lucie Larguier ,Ben Brahim ,Transgene Euronext ,Sylvie Berrebi ,Astrazeneca ,Twitter ,Corporate Communications ,European Society For Medical Oncology ,Nasdaq ,Euronext Paris ,Vaccinia Virus ,European Society ,Medical Oncology ,Artificial Intelligence ,Risk Factors ,Universal Registration Document ,Transgene ,Nnounces ,License ,Option ,Exercise ,Ncolytic ,Virus ,Enerated ,Tanvir ,Platform ,